康弘药业(002773) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 reached ¥1,092,784,087.91, representing a 23.50% increase compared to ¥884,838,651.01 in the same period last year[4] - Net profit attributable to shareholders was ¥373,521,473.06, up 33.72% from ¥279,331,041.04 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥362,972,028.39, reflecting a 36.18% increase from ¥266,531,188.33 in the previous year[4] - Basic and diluted earnings per share were both ¥0.41, up 36.67% from ¥0.30 in the previous year[4] - The company reported a gross profit margin of approximately 39.7%, compared to 36.2% in the previous year[28] Cash Flow and Liquidity - The net cash flow from operating activities was ¥405,935,869.60, a significant increase of 116.28% compared to ¥187,686,073.46 in the same quarter last year[4] - Cash and cash equivalents decreased to ¥3,112,962,184.64 from ¥4,702,142,704.60, a decline of 33.8%[24] - The company reported a net decrease in cash and cash equivalents of $1,597,428,914.87, compared to a decrease of $1,453,163,182.48 in the previous period[31] - The ending balance of cash and cash equivalents was $3,072,565,305.73, an increase from $2,122,513,089.46 in the previous period[31] - Cash paid to employees increased to $333,991,570.88 from $275,502,890.22, reflecting a rise of 21.2%[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,833,348,358.09, a 3.56% increase from ¥8,529,680,910.70 at the end of the previous year[4] - Total liabilities and equity amounted to ¥8,833,348,358.09, indicating a rise from ¥8,529,680,910.70[27] - Current liabilities decreased to ¥594,495,406.58 from ¥654,431,822.37, a reduction of about 9.16%[42] - Non-current liabilities decreased to ¥55,481,924.54 from ¥63,332,040.04, reflecting a decline of approximately 12.66%[42] - The company reported a significant reduction in accounts payable from ¥344,029,888.60 to ¥255,973,214.44, a decrease of about 25.6%[42] Segment Performance - The pharmaceutical manufacturing segment contributed ¥109,253.40 million, accounting for 99.98% of total revenue, with a year-on-year growth of 23.48%[4] - The biological medicine segment saw a significant increase of 59.00%, contributing ¥54,274.38 million, which is 49.67% of total revenue[4] Research and Development - Research and development expenses were ¥63,845,609.61, slightly down from ¥68,663,415.81 in Q1 2023[28] - The company continues to focus on research and development of new products and technologies to enhance market expansion strategies[43] Accounting and Standards - The company is set to implement new accounting standards starting in 2024, which may impact financial reporting[49]